Company

Location

Amount (US$M)

Round

Details

Date

Total: $1,346.88M

Achilles Therapeutics Ltd.

Stevenage, U.K.

$120.00

Series B

£100M (US$120M) series B round led by RA Capital Management, with other new investors, including Forbion, Invus, Perceptive Advisers and Redmile Group

9/4/19

Amphivena Therapeutics Inc.

South San Francisco

$62.00

Series C

$62M series C co-led by Nanodimension and Qiming Venture Partners USA, with new investors Clough Capital, Aju IB, Korys Merieux, Kaitai Capital, Industrial Investors, Nawton Ltd. and insiders MPM Capital, funds managed by Tekla and Franklin Berger

9/25/19

Anokion SA

Ecublens, Switzerland

$40.00

Series B

$40M series B financing led by Versant Ventures, Novartis Venture Fund, Novo Ventures alongside Swiss-based private investors

9/12/19

Arctoris Ltd.

Oxford, U.K.

$3.94

Seed

Seed funding round of £3.2M (US$3.94M) led by RT Partners, angel investors as well as additional investors and advisors

9/30/19

Boundless Bio Inc.

San Diego

$46.40

Series B

$46.4M series A financing co-led by Arch and City Hill Ventures, along with Vertex Ventures, GT Healthcare Capital Partners, Boxer Capital of the Tavistock Group, Alexandria Venture Investments, and other undisclosed investors

9/20/19

Curamir Therapeutics Inc.

Woburn, Mass.

$10.00

Series A

$10M series A financing led by Delos Capital

9/23/19

Edgewise Therapeutics Inc.

Boulder, Colo.

$50.00

Series B

$50M series B financing co-led by Novo Holdings A/S and U.S. Venture Partners with participation from Deerfield Management, New Leaf Venture Partners, Cure Duchenne Ventures and a founding investor, Orbimed Advisors

9/18/19

Edigene Inc.

Beijing

$11.00

Series pre-B2

$11M series pre-B2 financing round with series A lead investor IDG Capital and series pre-B lead investor Lilly Asia Ventures participating

9/17/19

Ermium Therapeutics

Paris

$6.90

Series A

Series A funding of €6.3M (US$6.9M) with Strasbourg, France-based Domain Therapeutics SA, Kurma Partners, Idinvest and the SATT Erganeo

9/12/19

Gaba Therapeutics Inc.

Newport Beach, Calif.

$15.50

Series A

Series A financing of up to $15.5M from Berlin-based Atai Life Sciences AG

9/23/19

Genenta Science Srl

Milan

$14.60

N/A

€13.2M (US$14.6M) in new funding led by Qianzhan Investment Management (QZ) and Fidim

9/11/19

GI Innovation Inc.

Seoul, South Korea

$31.00

Series B

KRW37.5B (US$31M) series B investment led by Yuhan Corp., DS Asset Management Co. Ltd., Ajou IB Investment Co. Ltd., Dayli Partners Inc. and Timefolio Asset Management Co. Ltd.

9/30/19

Gyroscope Therapeutics Ltd.

Stevenage, U.K.

$60.50

Series B

£50.4M (US$60.5M) series B round with Syncona providing £48M and remaining £2.4M by Cambridge Innovation Capital

9/4/19

Inotrem SA

Paris

$42.90

Series B

€39M (US$42.9M) in a series B round led by Morningside Ventures and Invus along with existing shareholders in Inotrem, Andera Partners, Sofinnova Partners and Biomedinvest

9/12/19

Insilico Medicine

Hong Kong

$37.00

Series B

$37M funding round led by Qiming Venture Partners, joined by Eight Roads, F-Prime Capital, Lilly Asia Ventures, Sinovation Ventures, Baidu Ventures, Pavilion Capital, Bold Capital Partners and other investors including series A investors

9/11/19

Ivexsol

Boston

$2.00

Seed

$2M in new convertible debt funding led by Casdin Capital LLC and Biolife Solutions

9/25/19

Linnaeus Therapeutics Inc.

Haddonfield, N.J.

$12.00

Series B

$12M series B financing led by Kairos Ventures with participation by the Penn Medicine Co-Investment Fund at the University of Pennsylvania

9/18/19

LNC Therapeutics SA

Bordeaux, France

$5.40

Seed

€4.9M (US$5.40M) from existing shareholders, including Seventure Partners, along with a new family office

9/6/19

Meissa Vaccines Inc.

South San Francisco

$30.00

Series A

$30M Series A financing with Morningside Ventures

9/26/19

Metacrine Inc.

San Diego

$50.00

Loan

Loan and security agreement worth up to $50M with the private equity-backed health care financier K2 Healthventures (K2HV). The agreement provides Metacrine with $10M of proceeds upfront, and the option to draw additional tranches based on the achievement of certain milestones through 2020

9/19/19

MGB Biopharma Ltd.

Glasgow, Scotland

N/A

Seed

Oversubscribed fundraising round supported by new and existing investors, led by Archangel Investors and including Scottish Investment Bank, Barwell and Tricapital Investors

9/3/19

Navrogen Inc.

Philadelphia

$3.20

Convert-ible note financing

$3.2M in a convertible note financing led by Ben Franklin Technology Partners of South Eastern Pennsylvania and several private investors

9/18/19

Nkarta Therapeutics Inc.

South San Francisco

$114.00

Series B

Oversubscribed $114M series B financing led by Samsara Biocapital, along with existing investors NEA Ventures, Novo Holdings A/S and SR One; Other new investors, include Amgen Ventures, Deerfield Management, Life Science Partners, Logos Capital and RA Capital Management

9/5/19

Novaremed AG

Basel, Switzerland

$2.63

Seed

CHF2.6M (US$2.63M) in additional financing from its existing shareholders and several new private investors

9/4/19

Oncocell MDx Inc.

Royal Oak, Mich.

$22.20

Series B

$22.2M in a series B financing led by Savitr Capital, with participation from existing investors

9/16/19

Passage Bio Inc.

Philadelphia

$110.00

Series B

$110M series B financing led by Access Biotechnology with participation from existing investors, including Orbimed, Frazier Healthcare Partners, Versant Ventures, Lily Asia Ventures, New Leaf Venture Partners and Vivo Capital, along with new investors Boxer Capital of Tavistock Group, Highline Capital Management, Logos Capital and Sphera Funds Management

9/5/19

Pharvaris BV

Leiden, the Netherlands

$66.00

Series B

$66M series B financing led by Foresite Capital together with Bain Capital Life Sciences, Venbio Partners and Venrock Partners, as well as existing investors LSP, Kurma Partners and Idinvest Partners

9/11/19

Platelet Biogenesis Inc.

Cambridge, Mass.

$26.00

Series A-1

More than $26M in a series A-1 financing co-led by Ziff Capital Partners and Qiming Venture Partners USA, with participation from existing investors Nest.Bio Ventures and Ecoast Angels

9/10/19

Polypid Ltd.

Petah Tikva, Israel

$50.00

Series E-1

$50M series E-1 preferred shares financing round led by existing institutional shareholders and included US-based high-net worth investors. National Securities Corp. acted as the placement agent for the financing

9/5/19

Repare Therapeutics Inc.

Montreal

$83.00

Series B

$82.5M series B round led by Cowen Healthcare Investments, Orbimed, Redmile, BVF Partners LP and Logos Capital, and founding investors Versant Ventures and other existing investors MPM Capital, Fonds de Solidarité FTQ and BDC Capital

9/5/19

Ribometrix Inc.

Durham, N.C.

$7.80

Seed

$7.8M in funding from additional investors, the Dementia Discovery Fund and Illumina Ventures

9/27/19

Spark Biopharma Inc.

Seoul, South Korea

$21.00

Series B

KRW25B (US$21M) in series B funding led by venture capital companies based in Korea, including KB Investment Co. Ltd., KTB Network Co. Ltd., Partners Investment Co. Ltd., IMM Investment Corp., E&Venture Partners Inc. and K Partners Ltd.

9/23/19

Stipe Therapeutics

Aarhus, Denmark

$21.76

Series A

€20M (US$21.76M) series A financing round co-led by Novo Holdings, Arix Bioscience plc, Wellington Partners Life Science V Fund and Sunstone Life Science Ventures A/S

9/30/19

Strekin AG

Basel, Switzerland

$2.85

Series A

Series A financing round totaling CHF2.82M (US$2.85M) from private investors

9/4/19

T3 Pharmaceuticals AG

Switzerland

$12.10

Seed

CHF12M (US$12.1M) in a second financing round led by the Boehringer Ingelheim Venture Fund and Reference Capital SA along with existing investors

9/27/19

Tacalyx GmbH

Berlin

$7.70

Seed

€7M (US$7.7M) in seed funding

9/26/19

Themis Bioscience GmbH

Vienna

$44.30

Series D

€40M (US$44.3M) series D round co-led by Farallon Capital, Hadean Ventures, Merck & Co. Inc. and Adjuvant Capital. Existing shareholders Global Health Investment Fund, AWS Gruenderfonds, Omnes Capital, Ventech and Wellington Partners Life Sciences, also participated

9/19/19

Trucode Gene Repair Inc.

San Francisco

$34.00

Seed

Raised $34M from investors, including Kleiner Perkins and GV

9/11/19

Vedanta Biosciences Inc.

Cambridge, Mass.

$16.60

Series C-2

$16.6M in a series C-2 financing led by Quad Investment Management, SV Investment Corp., Shinhan Investment-Private Equity, Shinhan Capital-Yeollim Partners, Partners Investment Co. Ltd., FC Capital, Symbiosis LLC, the Bill & Melinda Gates Foundation, Bristol-Myers Squibb Co., Rock Springs Capital, JSR Corp. Shumway Capital, Invesco Asset Management, Health for Life (Seventure Partners) and Puretech Health

9/24/19

Veralox Therapeutics Inc.

Frederick, Md.

$5.40

Seed

$5.4M seed funding led by the JDRF T1D Fund, Sanofi Ventures and the VTC Innovation and VTC Seed Fund, with participation from the Maryland Momentum Fund, the University of Vermont Health Network and Tedco

9/6/19

Versantis AG

Zurich, Switzerland

$16.10

Series B

CHF16M (US$16.1M) in a series B round led by Zürcher Kantonalbank and other new investors, include Esperante Ventures, Investiere. several undisclosed private investors and existing shareholders Redalpine Healthequity, and Zurcher Kantonalbank Start-up Finance also participated

9/19/19

Zielbio Inc.

Charlottesville, Va.

$25.10

Series A

$25.1M series A financing led by Morningside Venture Investments and Partners Innovation Fund

9/27/19

Zylo Therapeutics LLC

Greenville, S.C

$4.00

Series A

Series A financing through the sale of $4M of series A preferred shares. Approx. $1.35M of that total was invested prior to this year and the remaining $2.65M was newly invested capital, led by Venturesouth with investments totaling more than $1M. Other angel groups investing in the round, include the New York Angels, Ariel Southeast Angel Partners, the Boston Harbor Angels and the Chemical Angel Network

9/27/19


Notes

Currency conversions are based on exchange rates at the time of the deal.

This chart includes only biotech companies that develop therapeutics.

No Comments